Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 11;116(8):1012-1020.
doi: 10.1038/bjc.2017.52. Epub 2017 Mar 9.

Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system

Jeong Mo Bae  1   2 , Jung Ho Kim  1   3 , Yoonjin Kwak  3   4 , Dae-Won Lee  5 , Yongjun Cha  5 , Xianyu Wen  1 , Tae Hun Lee  1 , Nam-Yun Cho  1 , Seung-Yong Jeong  6 , Kyu Joo Park  6 , Sae Won Han  5 , Hye Seung Lee  3   4 , Tae-You Kim  5 , Gyeong Hoon Kang  1   3
Affiliations

Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system

Jeong Mo Bae et al. Br J Cancer. .

Abstract

Background: Colorectal cancer (CRC) is a heterogeneous disease in terms of molecular carcinogenic pathways. Based on recent findings regarding the multiple serrated neoplasia pathway, we revised an eight-marker panel for a new CIMP classification system.

Methods: 1370 patients who received surgical resection for CRCs were classified into three CIMP subtypes (CIMP-N: 0-4 methylated markers, CIMP-P1: 5-6 methylated markers and CIMP-P2: 7-8 methylated markers). Our findings were validated in a separate set of high-risk stage II or stage III CRCs receiving adjuvant fluoropyrimidine plus oxaliplatin (n=950).

Results: A total of 1287/62/21 CRCs cases were classified as CIMP-N/CIMP-P1/CIMP-P2, respectively. CIMP-N showed male predominance, distal location, lower T, N category and devoid of BRAF mutation, microsatellite instability (MSI) and MLH1 methylation. CIMP-P1 showed female predominance, proximal location, advanced TNM stage, mild decrease of CK20 and CDX2 expression, mild increase of CK7 expression, BRAF mutation, MSI and MLH1 methylation. CIMP-P2 showed older age, female predominance, proximal location, advanced T category, markedly reduced CK20 and CDX2 expression, rare KRAS mutation, high frequency of CK7 expression, BRAF mutation, MSI and MLH1 methylation. CIMP-N showed better 5-year cancer-specific survival (CSS; HR=0.47; 95% CI: 0.28-0.78) in discovery set and better 5-year relapse-free survival (RFS; HR=0.50; 95% CI: 0.29-0.88) in validation set compared with CIMP-P1. CIMP-P2 showed marginally better 5-year CSS (HR=0.28, 95% CI: 0.07-1.22) in discovery set and marginally better 5-year RFS (HR=0.21, 95% CI: 0.05-0.92) in validation set compared with CIMP-P1.

Conclusions: CIMP subtypes classified using our revised system showed different clinical outcomes, demonstrating the heterogeneity of multiple serrated precursors of CIMP-positive CRCs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Molecular characteristics of colorectal cancers in the discovery set in relation to the number of methylated genes (N=1370).
Figure 2
Figure 2
Cancer-specific survival of patients in the discovery set (N=1243) in relation to the revised CIMP classification system.
Figure 3
Figure 3
Relapse-free survival of patients in the validation set (N=950) in relation to the revised CIMP classification system.
Figure 4
Figure 4
Molecular sub-classification of CIMP-positive colorectal cancers and their putative precursors.CA=conventional adenoma; MSS=microsatellite stable; MSI=microsatellite instability; SSA=sessile serrated adenoma; TSA=traditional serrated adenoma; TVA=tubulovillous adenoma.
See this image and copyright information in PMC

Comment in

References

    1. Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Moehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Flejou JF, de Gramont A (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC Study. J Clin Oncol 33(35): 4176–4187. - PubMed
    1. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH (2013) Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 109(4): 1004–1012. - PMC - PubMed
    1. Bae JM, Lee TH, Cho NY, Kim TY, Kang GH (2015) Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol 21(5): 1457–1467. - PMC - PubMed
    1. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F (2008) Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 68(20): 8541–8546. - PubMed
    1. Bettington M, Walker N, Rosty C, Brown I, Clouston A, McKeone D, Pearson SA, Klein K, Leggett B, Whitehall V (2016) Serrated tubulovillous adenoma of the large intestine. Histopathology 68(4): 578–587. - PubMed

MeSH terms

Substances